News in therapeutic management of chronic lymphoid leukemia;Actualités thérapeutiques de la leucémie lymphoïde chronique

Bulletin du Cancer

Volumn 92, Issue 3, 2005, Pages 249-256

  Michallet, Anne Sophie ^a   Salles, Gilles ^a   Coiffier, Bernard ^a   Michallet, Mauricette ^a  

^a EDOUARD HERRIOT HOSPITAL   (France)

Author keywords

Chronic lymphocytic leukemia; Therapy

Indexed keywords

ALEMTUZUMAB; ANTINEOPLASTIC AGENT; CD38 ANTIGEN; CYCLOPHOSPHAMIDE; CYTOSTATIC AGENT; FLUDARABINE; IMMUNOGLOBULIN; MONOCLONAL ANTIBODY; PROTEIN KINASE ZAP 70; PURINE DERIVATIVE; RITUXIMAB; CANCER ANTIBODY; DRUG DERIVATIVE; VIDARABINE;

AGE; ALLOGENEIC STEM CELL TRANSPLANTATION; CANCER COMBINATION CHEMOTHERAPY; CANCER MORTALITY; CANCER REGRESSION; CANCER RELAPSE; CANCER STAGING; CANCER SURVIVAL; CHROMOSOME 11Q; CHROMOSOME ABERRATION; CHRONIC LYMPHATIC LEUKEMIA; COMORBIDITY; DISEASE COURSE; DRUG EFFICACY; DRUG SAFETY; FLUORESCENCE IN SITU HYBRIDIZATION; FOLLOW UP; GENE DELETION; GENE MUTATION; GRAFT VERSUS LEUKEMIA EFFECT; HEMOLYTIC ANEMIA; HUMAN; IMMUNE DEFICIENCY; INFECTION; LYMPHADENOPATHY; NEUTROPENIA; OPPORTUNISTIC INFECTION; PROGNOSIS; PROTEIN EXPRESSION; REDUCED INTENSITY CONDITIONING; REVIEW; SYMPTOM; THROMBOCYTOPENIA; GENETICS; HEMATOPOIETIC STEM CELL TRANSPLANTATION;

AGE FACTORS; ANTIBODIES, MONOCLONAL; ANTIBODIES, NEOPLASM; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CYCLOPHOSPHAMIDE; DISEASE PROGRESSION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; LEUKEMIA, LYMPHOCYTIC, CHRONIC; PROGNOSIS; VIDARABINE;

EID: 17144378183     PISSN: 00074551     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (44)

1. Rai KR, Sawitsky A, Cronkite EP, Chanana AD, Ling KN, Pasternack BS, et al. Clinical staging of chronic lymphocytic leukemia. Blood 1975; 46: 219-34.
2. Binet JL, Auquier A, Dighiero G, Chastang C, Piquet H, Goasquen J, et al. A new pronostic classification of chronic lymphocytic leukemia derived from a mulrivariate survival analysis. Cancer 1981; 48: 198-206.
3. Molica S, Alberti A. Pronostic value of the lymphocyte doubling time in chronic lymphocytic leukemia. Cancer 1987; 60: 2712-6.
4. Sarfati M, Chevret S, Chastang C, Biron G, Stryckmans P, Delesperse G, et al. Pronostic importance of serum soluble CD23 level in chronic lymphocytic leukaemia. Blood 1996; 88: 4259-64.
5. Hallek M, Langenmayer I, Nerl C, Knauf W, Dietzfelbinger H, Adorf D, et al. Elevated serum thymidine kinase levels identify a subgroup at high risk of disease progression in early non smoldering chronic lymphocytic leukaemia. Blood 1999; 93: 1732-7.
6. Dohner H, Stilgenbauer S, Bennet A, Leupolt E, Krober A, Bullinger L, et al. Genomic aberrations and survival in chronic lymphocytic leukemia. N Engl J Med 2000; 343: 1910-6.
7. Hamblin TJ, Davis Z, Gardiner A, Oscier DG, Stevenson FK. Unmutated IgV (H) genes are associated with a more aggressive form of chronic lymphocytic leukemia. Blood 1999; 94: 1848-54.
8. Damle RN, Wasil T, Fais F, Ghiotto F, Valetto A, Allen SL, et al. IgV gene mutation status and CD38 expression as novel prognostic indicators in chronic lymphocytic leukemia. Blood 1999; 94: 1840-7.
9. Kröber A, Seiler T, Benner A, Bullinger L, Bruckle E, Lichter P, et al. V(H) mutation status, CD38 expression, genomic aberrations, and survival in chronic lymphocytic leukemia. Blood 2002; 100: 1410-6.
10. Hamblin TJ, Orchard JA, Gardiner A, Oscier DG, Davis Z, Stevenson FK. Immunoglobulin V genes and CD38 expression in CLL. Blood 2000; 95: 2455-7.
11. Oscier DG, Gardiner A, Mould SJ, Glide S, Davis Z, Ibboston RE, et al. Multivariate analysis of prognostic factors in CLL: clinical stage, IgGV(H) gene mutational status, ans loss or mutation of the p53 are independent prognostic factors. Blood 2002; 100: 1177-84.
12. Chen L, Widhopf G, Huynh L, Rassenti L, Raik R, Weiss A, et al. Expression of ZAP-70 is associated with increased B-cell receptor signaling in chronic lymphocytic leukemia. Blood 2002; 100: 4609-14.
13. Rosenwald A, Alizadeh AA, Widhopf G, Simon R, Davis RE, Yu X, et al. Relation of gene expression phenotype to immunoglobulin mutation genotype in B cell chronic lymphocytic leukemia. J Exp Med 2001; 194: 1639-47.
14. Kim SZ, Chow KU, Kukoc-Zivojnov N, Boehrer S, Brieger A, Steinle-Grauer SA, et al. Expression of ZAP-70 protein correlated with disease stage chonic lymphocytic leukemia and is associated with but not generally restricted to non-mutated IgV (H) status. Leuk Lymphoma 2004; 45: 2037-45.
15. Crespo M, Bosch F, Villamor N, Bellosillo B, Colomer D, Rozman M, et al. ZAP-70 expression as a surrogate for immunoglobulin-variable-region mutations in chronic lymphocytic leukaemia. N Engl J Med 2003; 348: 1764-75.
16. Shanafelr TD, Geyer SM, Kay NE. Pronostic at diagnosis: integrating molecular biologic insights into clinical practice for patients with CLL. Blood 2004; 103: 1202-10.
17. Klein U, Tu Y, Stolovitzky GA, Martioli M, Catoretti G, Husson H, et al. Gene expression profiling of B cell chronic lymphocytic leukemia reveals a homogeneous phenotype related to memory B cells. J Exp Med 2001; 194: 1025-38.
18. Haslinger C, Schweifer N, Stilgenbauer S, Dohner H, Lichter P, Kraut N, et al. Microarray gene expression profiling of B-cell chronic lymphocytic leukemia subgroups defined by genomic aberrations and VH mutation status. J Clin Oncol 2004; 22: 3937-49.
19. O'Brien S, Kantarjian HM, Cortes J, Beran M, Koller CA, Giles FJ, et al. Results of a fludarabine and cyclophosphamide combination regimen in chronic lymphocytic leukemia. J Clin Oncol 2001; 19: 1414-20.
20. Hallek M, Schmitt B, Wilhelm M, Bush R, Krober A, Fostitsch HP, et al. Fludarabine plus cyclophosphamide is an efficient treatment for advanced chronic lymphocytic leukemia (CLL): results of a phase II study of the German CLL group. Br J Hematol 2001; 114: 342-8.
21. Tournilhac O, Cazin B, Lepretre S, Divine M, Maloum K, Delmer A, et al. Impact of frontline fludarabine and cyclophosphamide combined treatment on peripheral blood stem cell mobilization in B-cell chronic lymphocytic leukemia. Blood 2004; 103: 363-5.
22. Coiffier B, Lepage E, Briere J, Herbrecht R, Tilly H, Bouabdallah R, et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large cell lymphoma. N Engl J Med 2002; 346: 235-42.
23. Schulz H, Klein SK, Rehwald U, Reiset M, Hinke A, Knaufa W, et al. Phase 2 study of a combined immunochemotherapy using rituximab and fludarabine in patients with chronic lymphocytic leukemia. Blood 2002; 100: 3115-20.
24. Byrd JC, Peterson BL, Morrison VA, Park K, Jacobson R, Hoke E, et al. Randomized phase 2 study of fludarabine with concurrent versus sequential treatment with rituximab in symptomatic, untreated patients with B-cell chronic lymphocytic leukaemia: results from Cancer and Leukemia Group B 9712 (CALGB 9712). Blood 2003; 101: 6-14.
25. Wierda W. Combined fludarabine, cyclophosphamide and rituximab achieves a high complete remission rate as initial treatment for chronic lymphocytic leukemia. Blood 2001; 98: 771a.
26. Keating MJ, Manshouri T, O'Brien O. A high proportion of true complete remission can be obtained with fludarabine, cyclophosphamide, rituximab combination (FCR) in chronic lymphocytic leukemia. J Clin Oncol 2003; 21: 2289a.
27. Lundin J, Hasberg H, Repp R, Cavallin-Stahl E, Freden S, Juliusson G, et al. Phase 2 study of alemtuzumab (anti-CD52 monoclonal antibody) in patients with advanced mycosis fungoides/Sezary syndrome. Blood 2003; 101: 4267-72.
28. Österborg A, Dyer MJ, Bunjes D, Pangalis GA, Bastion Y, Catovsky D, et al. Phase II multicenter study of human CD52 antibody in previously treated chronic lymphocytic leukaemia. European Study Group of Campath-1H treatment in chronic lymphocytic leukemia. J Clin Oncol 1997; 15: 1567-74.
29. Bowen AL, Zomas A, Emmett E, Matutes E, Dyer MJ, Catovsky D, et al. Subcutaneous Campath-1H in fludarabine-resistant/relapsed chronic lymphocytic and B-prolymphocytic leukemia. Br J Hematol 1997; 96: 617-9.
30. Dyet MJ, Kelsey SM, Mackay HJ, Emmett E, Thornton P, Hale G, et al. In vivo «purging» of tesidual disease in CLL with Campath-1H. Br J Hematol 1997; 97: 669-72.
31. McCune SL, Gockerman JP, Moore JO, De Castro CM, Bass AJ, Chao NJ, et al. Alemtuzumab in telapsed or refractory chronic lymphocytic leukaemia and prolymphocytic leukaemia. Leuk Lymphoma 2002; 43: 1007-11.
32. Keating MJ, Flinn I, Jain V, Binet JL, Hillmen P, Byrd A, et al. Therapeutic role of alemtuzumab (Campath-1H) in patients who failed fludatabine: results of a large international. Blood 2002; 99: 3354-61.
33. Thieblemont C, Bouafia F, Hotnez E, Dumontet C, Tartas S, Antal D, et al. Maintenance therapy with a montly injection of Campath-1H in refractory chronic leukemia and NHL patients. Blood 2002; 100: 805a.
34. Thieblemont C, Bouafia F, Hotnez E, Dumontet C, Tactas S, Antal D, et al. Maintenance therapy with a montly injection of alemtuzumab prolongs response duration in patients with refractory B-cell chronic lymphocytic leukemia/small lymphocytic lymphoma (B-CLL/SLL). Leuk Lymphoma 2004; 45: 711-4.
35. Michallet M, Carreras E, Cotnelissen JJ. Allotransplants and autotransplants in CLL. Bone Marrow Transplant 1999; 23: 53a.
36. Michallet M, Brand R, Dreger P. Analysis of prognostic factors and the outcome of autologous and allogeneic stem cell transplantations for chronic lymphocytic leukaemia. Blood 2001; 98: 3568a.
37. Michallett M, Archimbaud E, Bandini G, Rowlings PA, Deeg HJ, Gahrton G, et al. HLA-identical sibling bone marrow transplants for chronic lymphocytic leukaemia. Ann Intern Med 1996; 124: 311-6.
38. Milligan D, Fernandes S, Dasgupta R, Davies FE, Matutes E, Fagon CD, et al. Autografting for younger patients with chronic lymphocytic leukemia is safe and achieves a high percentage of molecular responses: results of the MRC pilot study. Blood 2005 (sous presse).
39. Dreger P, Stilgenbauer S, Benner A, Ritgen M, Krober A, Kneba M. The pronostic impact of autologous stem cell transplantation in patients with chronic lymphocytic leukemia: a risk matched analysis based on VH mutational status. Blood 2004; 103: 2850-8.
40. Ritgen M, Stilgenbauer S, Von Neuhoff N, Humpe A, Bruggemann M, Raff T, et al. Graft-versus-leukemia activity may overcome therapeutic response of chronic lymphocytic leukemia with unmutated immunoglobuline variable heavy-chain gene status: implications of minimal residual disease measurement with quantitative PCR. Blood 2004; 104: 2600-2.
41. Khouri IF, Saliba RM, Giralt SA, Lee MS, Okaroji GJ, Hagemeister FB. Non ablative allogeneic hematopoietic transplantation as adoptive immunotherapy for indolent lymphoma: low incidence of toxicity, acute graft-versus-host disease and transplant-related mortality. Blood 2001; 98: 3595-9.
42. Michallet M, Bilger K, Garban F, Attal M, Huyn A, Blaise D, et al. Allogeneic hematopoietic stem cell transplantation after nonmyeloablative preparative regimen: impact of pretransplantation and posttransplantation factors on outcome. J Clin Oncol 2001; 19: 2240-9.
43. Dreget P, Brand R, Hansz J, Milligan D, Cottadini P, Finke J, et al. Treatment-related mortality and graft-versus-leukemia activity after allogeneic stem cell transplantation for chronic lymphocytic leukemia using intensity-reduced conditioning. Leukemia 2003; 17: 841-8.
44. Khouti IF, Lee MS, Saliba RM, Andersson B, Anderlini P, Coutiel D, et al. Nonablative allogeneic stem cell transplantation for chronic lymphocytic leukemia: impact of rituximab on immunomodulation and survival. Exp Hematol 2004; 32: 28-35.